Staging of pancreatic cancer based on the number of positive lymph nodes. BJS 2017; 104: 608-618.
Published: 14th February 2017
Authors: I. Tarantino, R. Warschkow, T. Hackert, B. M. Schmied, M. W. Büchler, O. Strobel et al.
The International Study Group on Pancreatic Surgery has stated that at least 12 lymph nodes should be evaluated for staging of pancreatic cancer. The aim of this population‐based study was to evaluate whether the number of positive lymph nodes refines staging.
Patients who underwent pancreatectomy for stage I–
Some 5036 patients were included, with a median of 18 (i.q.r. 15–24) lymph nodes examined. Positive lymph nodes were found in 3555 patients (70·6 per cent). The median duration of follow‐up was 15 (i.q.r. 8–28) months.
The number of positive lymph nodes in the resection specimen is a prognostic factor in patients with pancreatic cancer.Read more
You may also be interested in
Survival following liver transplantation for liver‐only colorectal metastases compared with hepatocellular carcinoma.
Authors: S. Dueland, A. Foss, J. M. Solheim, M. Hagness, P.‐D. Line
Notes: Valid treatment option for colorectal liver metastases
Propensity score‐matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection.
Authors: M. Raoof, P. H. G. Ituarte, Y. Woo, S. G. Warner, G. Singh, Y. Fong et al.
Notes: No difference in survival
Authors: M. G. Keane, A. Shamali, L. N. Nilsson, A. Antila, J. Millastre Bocos, M. Marijinissen Van Zanten et al.
Notes: Low risk in small, asymptomatic mucinous cystic neoplasms
Authors: A. ten Hove, V. E. de Meijer, J. B. F. Hulscher, R. H. J. de Kleine
Notes: Choledochal cysts should be resected
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy. BJS 2018; 105: 339-349.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation. BJS 2018; 105: 328-338.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results